UNSPSC 51112008: Sorafenib

This classification denotes a protein kinase inhibitor with the molecular formula C21H16ClF3N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9ZOQ3TZI87, chemically known as 2-pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-n-methyl- but generally known as sorafenib, which bears US NIH Compound Identifier 216239. European Medicines Agency schedules Sorafenib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB23139.

UNSPSC 51112008 Sorafenib is a Commodity code designating a specific pharmaceutical active pharmaceutical ingredient, but state and local procurement activity under this code reflects broader generic multi-source pharmaceutical procurement rather than sorafenib specifically. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 for generic multi-source pharmaceuticals and over-the-counter products to supply participating state and local government facilities across multiple states including Oregon. Work under this code involves manufacturers providing comprehensive pricing for identified pharmaceutical products with specific National Drug Codes (NDCs), including detailed product information, compliance certifications, and pricing flexibility through formats such as flat price, net price (NF30, NF60, NF90), or WAC-minus structures. Vendors must certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), and carry comprehensive insurance including $5,000,000 commercial general liability per occurrence. Evaluation weighting prioritizes price competitiveness (75 percent) followed by fixed pricing for the contract term (10 percent), compliance with administrative fee data format requirements (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent).

MMCAP represents a multistate cooperative purchasing vehicle with participation from state and local government facilities across at least two states. The January 2026 RFP (Solicitation S1070000015802) specified a March 26, 2026 response deadline, with awarded vendors to be provided to authorized wholesalers by May 15, 2026 and resulting agreements effective July 1, 2026. The contract term runs two years for new responders with optional extensions at MMCAP's sole discretion, while incumbent vendor amendments extend through June 30, 2028. MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations, product availability, patient safety, and member-specific needs. No specific award values or budget ranges were disclosed in the available solicitation materials, but all contract purchases are subject to a 3 percent administrative fee and performance penalties ranging from $200 to $1,500 per violation.